The Acorda Therapeutics, Inc. (NASDAQ:ACOR) second quarter 2023 financial and business update provided today by the company's CFO, Tierney Saccavino, is providing an update on the company's second quarter 2023 financial and business update.  According to the company's investor alert, on August 8, 2018, the company announced that it would be raising its sales guidance for the second quarter of 2023.  According to the SEC's alert, the company's new guidance for the second quarter of 2023 represents a 12% increase over the first half of the year and represents substantial growth over the first half of the year.  The company also announced that it would be raising its guidance for the second half of the year.  The company's website and brand campaign highlights that the return of symptoms or OFF periods between regular doses of INBRIJA may cause people with Parkinson's to avoid important moments of their lives such as those related to their family or friends, their interest, their exercise.  The company is also continuing to evaluate collaborations for creating important new inhaled therapies.  The company's field sales team continues to call on its field sales specialists to ensure that they're aware of the support that we're providing for the brand.  The company also recently launched a new consumer INBRIJA website and brand campaign.  The website and brand campaign are called "For the Fighters."  The website and brand campaign is called "For the Fighters."  The company's investor alert encourages investors to check the background of anyone selling or offering them an investment using the free and simple search tool on Investor.gov.